Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.54 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11022943 | 0.83 | HDAC1 (0.65) | POLBUSP2ALDH1A1MEN1KMT2A | |
| SCHEMBL10154070 | 0.83 | POLB (0.60) | POLBUSP2ALDH1A1MEN1KMT2A | |
| SCHEMBL6496853 | 0.81 | POLB (0.59) | POLBUSP2ALDH1A1MEN1KMT2A | |
| SCHEMBL968090 | 0.81 | POLB (0.59) | POLBUSP2ALDH1A1MEN1KMT2A | |
| SCHEMBL15831226 | 0.80 | POLB (0.58) | POLBUSP2ALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL378705 | 0.79 | SMN1; SMN2 (0.61) | POLBUSP2ALDH1A1MEN1KMT2A | |
| SCHEMBL31249652 | 0.79 | SMN1; SMN2 (0.61) | POLBUSP2ALDH1A1MEN1KMT2A | |
| SCHEMBL21980986 | 0.79 | USP2 (0.59) | POLBUSP2ALDH1A1MEN1KMT2A | |
| SCHEMBL4071390 | 0.79 | CTBP2 (0.64) | POLBUSP2ALDH1A1MEN1KMT2A | |
| SCHEMBL5103284 | 0.78 | USP2 (0.84) | POLBUSP2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178668-B2 | 2-aminopyridine kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2012-05-15 | — | — | US | disclosed |
| EP-2265270-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009099982-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197862-A1 | 2-AMINOPYRIDINE KINASE INHIBITORS | ERBB2, ABL2, TIE1 | POLB 4137/4885USP2 3415/4885ALDH1A1 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.